Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 10Triple Negative Breast Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Glioma 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma, Endometrioid 1

Interventions

Paclitaxel 17Carboplatin 16Magnetic Resonance Spectroscopy 11Taxes 10Specimen Handling 10Bevacizumab 10olaparib 9Gemcitabine 9pembrolizumab 8Immunoglobulin G 7Disulfides 7Biopsy 7liposomal doxorubicin 6Doxorubicin 5cediranib 4Nivolumab 4Cyclophosphamide 4Cisplatin 4oregovomab 3niraparib 3adavosertib 3X-Rays 3Topotecan 3tremelimumab 2rucaparib 2mirvetuximab soravtansine 2berzosertib 2aldesleukin 2Surveys and Questionnaires 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fallopian Tube Neoplasms × capivasertib × Clear all
NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
159 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡